Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. The Vascepa (icosapent ethyl capsules) is a single-molecule prescription product in use to reduce the risk of cardiovascular events.


TSX:HLS - Post by User

Bullboard Posts
Post by goldpigon Mar 23, 2012 2:23pm
592 Views
Post# 19710983

$25 Million Claim against GM

$25 Million Claim against GM

From the recent 2011 annual report,,,,,,,,,,,

 

GM LITIGATION UPDATE

Automodular has commenced a claim (the "Claim") against General Motors Company and General Motors of Canada Ltd. (collectively, "GM"), and Inteva Products, LLC and Inteva Products Canada ULC (collectively,"Inteva"). The Claim relates to a contract (the "Contract") between GM and Automodular for the sequencingand sub-assembly of components and modules for the Chevrolet Camaro.

 

By letter dated April 13, 2010, GM terminated the Contract effective September 20, 2010. GM has entered into a contract with Inteva for the same work that Automodular was performing under the Contract.

 

Automodular alleges GM's termination of the Contract was wrongful and in breach of the Contract. Automodular claims $20 million against GM for breach of contract and against Inteva for inducing breach of contract. Automodular also seeks punitive damages in the amount of $5 million. The statement of claim was issued on May 13, 2011 and served upon GM and Inteva.

 

The defendants have delivered statements of defence contesting the claims. The action has been commenced in the Ontario Superior Court of Justice.,,,,,,,,,,,,,,,,

 

AM exit  and impairment costs were about $9 million or so due to this cancellation.

An out of court settlement is most likley here with AM to recover its exit costs.

Bullboard Posts